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Abstract 
The application of chemical kinetics is one of the most powerful and versatile tools for 
investigating reaction mechanisms in complex mixtures. Kinetic studies are commonplace in 
traditional synthetic chemistry but are seldom used in radiopharmaceutical sciences. When 
deriving standard reaction rate laws the focus is normally placed on calculating the chemical 
concentration of different species over time. In radiopharmaceutical synthesis, the desired product 
is one of the radioactive components of the mixture. Reaction conditions are optimised to obtain 
the radioactive product in the highest activity yield. When short-lived radionuclides are used, 
radioactive decay during the reaction window means that the maximum activity yield does not 
necessarily coincide with the chemical or decay-corrected radiochemical yields. To account for 
this difference in the kinetic models, it is shown how standard integrated rate laws can be modify 
to incorporate the contribution from radioactive decay. An example is then presented to show how 
radiochemical kinetics can be used to model complex systems, like [18F]FDG radiosynthesis, that 
involve parallel or competing reactions at the different chemical scales of the radionuclide and 
substrate. Increased knowledge of reaction rates, and a more wide-spread application of 
radiochemical kinetics, can facilitate the development of new radiolabelling reactions. Accurate 
identification of maximum activity yields using kinetic models also has the potential to improve 
the optimisation and radiochemical efficiency of all current and future radiopharmaceutical 
syntheses. 
 
Keywords: Radiochemistry, chemical kinetics, molar activity, pseudo-first-order, second-order, 
activity yield, fluorine-18, carbon-11, gallium-68, zirconium-89, positron emission tomography 
(PET). 
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Introduction 
Chemical kinetics is the study of the rate (or velocity) of chemical reactions during which reactants 
are converted to products along a reaction coordinate.(1,2) Kinetic experiments usually involve 
measuring the concentration of a species versus time. Other macroscopic or ‘classical’ variables 
that influence reaction rates include changes in temperature, pressure, solvent composition, ionic 
strength, heat and entropy etc. When empirical data on reaction kinetics are combined with 
thermodynamics, molecular spectroscopy and transition state theory, it allows complex chemical 
processes to be deconvoluted into the underlying elementary steps that define our concept of 
reaction mechanisms. Methods derived from statistical thermodynamics can also be used to bridge 
the gap between the macroscopic and microscopic (or quantum chemical) world. Quantum 
descriptions allow reaction mechanisms to be explained at the atomic or molecular level. Kinetic 
investigations that integrate classical and quantum theories are referred to as the study of molecular 
reaction dynamics. 
 Kinetic experiments have access to a rich pool of analytical techniques. Traditional 
methods for monitoring the concentration of a species over time include time-resolved electronic 
absorption, infrared, NMR or fluorescence-emission spectroscopy, electrochemistry, 
potentiometry, and radioactive probes coupled with chromatography or chemical separation. The 
first use of radioactivity to measure kinetics can be traced back to the work of George de Hevesy 
and the invention of the radiotracer principle in 1923. Later, he received the Nobel Prize in 
Chemistry in 1943 for using radioactivity to study various chemical processes including transport 
and metabolism in plants and animals.(3–5) 
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Radiotracers are ideally suited for studying kinetics for several reasons.(6) First, accurate 
detection and quantification of radioactivity is possible even when species are present at extremely 
low concentrations (sub-femtomolar). Second, this high sensitivity means that radiotracers can be 
used at concentrations that do not perturb the original kinetic (or thermodynamic) process under 
investigation. Finally, many different radionuclides are available which means that it is possible 
to select or synthesise radiotracers that are chemically identical to the reacting species. In this 
respect, organic compounds labelled with 3H(t1/2 = 12.32 y), 14C(t1/2 = 5700 y), 32P(t1/2 = 14.268 
d), and 35S(t1/2 = 87.37 d) are frequently used in drug development to measure target binding 
properties in vitro, as well as absorption, distribution metabolism and excretion in vivo. Biological 
assays that use radiotracers include, for example, the measurement of enzyme-catalysed reactions 
using 32P- or 35S-labelled adenosine triphosphate.(7)  
The use of radiopharmaceuticals for diagnostic imaging or molecularly target radionuclide 
therapy is a core discipline in modern Nuclear Medicine. In contrast to the use of radiotracers in 
chemical or enzymatic assays, radiopharmaceutical synthesis usually involves working with 
radionuclides that have comparatively short half-lives.(8,9) For instance, imaging agents for 
positron emission tomography (PET) often utilise 11C(t1/2 = 20.364 min.), 13N(t1/2 = 9.965 min.), 
18F(t1/2 = 109.7 min.), 64Cu(t1/2 = 12.701 h), 68Ga(t1/2 = 67.71 min.), and 89Zr(t1/2 = 78.41 h). Here, 
the radioactive product is the desired species. The challenge is that the entire synthetic process 
must be completed on a time scale that gives sufficient activity for further use in imaging or 
therapy. Radiopharmaceutical production can be divided into two time-critical steps: i) 
radiochemical synthesis, and ii) quality control and release of the isolated product. Optimisation 
of quality control procedures is beyond the scope of this article. Due to the time constraints, 
efficient radiopharmaceutical synthesis is strongly dependent on reaction rates. Radiolabelling 
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reactions are frequently ‘optimised’ empirically to give the highest decay-corrected radiochemical 
yield (RCY) in the shortest time, but actual reaction rates (and rate constants) are rarely 
determined.  
The application of advanced chemical kinetics in radiopharmaceutical science has great 
potential to improve and streamline the process of optimising new (and existing) radiolabelling 
reactions. The problem is that kinetics models that focus on the activity of a radioactive component 
of the mixture as the primary variable are absent from standard texts.(1,2,10–14) In this 
perspective, the theory of chemical kinetics is extended to account for radioactive decay during 
the reaction/process. Analytical solutions and graphical plots are used to illustrate that maximum 
chemical and radiochemical yields do not coincide with maximum activity yield in first- and 
second-order radiochemical reactions with short-lived radionuclides. By extension, it is shown that 
the decay-corrected RCY is not the most appropriate variable to use when optimising these 
radiolabelling reactions. Finally, examples using data from the clinical production of four PET 
radiopharmaceuticals: [11C]raclopride,(15–17) 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG),(18) 
[68Ga]GaPSMA-11,(19) and the antibody-based agent [89Zr]Zr-DFO-J591 are presented (Figure 
1).(20–22) The primary motivation of this work is to show how radiochemistry can be integrated 
more closely with traditional curricula of the chemical sciences for mutual benefit. Ultimately, a 
more wide-spread use of chemical kinetics would help radiochemists to identify new reactions that 
have potential in radiochemistry, and reduce the time spent optimising reactions when new 
precursors/substrates or reactions become available. 
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The theory of radiolabelling kinetics 
Activity yield as the key variable 
Before examining the chemical kinetics of radiolabelling reactions, it is important to define the 
variables. Current nomenclature rules and parameter definitions given in the consensus report by 
Coenen et al. are used throughout.(23) By definition, the RCY is the amount of activity in the 
product expressed as a percentage (%) of the starting activity used in the considered process (for 
example, synthesis, separation, etc.), where both quantities refer to the same radionuclide, and are 
decay corrected to the same point in time before the calculation is performed. The RCY is an 
important value in radiochemical synthesis, but it is not the most useful variable when studying or 
optimising radiochemical kinetics where the goal is normally to obtain the maximum activity of 
the desired radioactive product. 
Consider a quantitative reaction between a radioactive species (A), and a radiolabelling 
precursor/substrate (B), that gives a single isolated product (P) with no material losses (Equation 
1). The second-order rate constant is given by k2 (M-1 s-1). A	 + 	B	 %&→ 	P  (Equation 1) 
At the end of the reaction, the decay-corrected RCY is equal to the chemical yield (calculated 
using the radioactive species as the limiting reagent), and both equal 100%. In reactions where no 
appreciable radioactive decay occurs during the experiment, such as those involving long-lived 
radionuclides and/or very short reaction times, optimisation based on the chemical yield or decay-
corrected RCYs is sufficient. However, in processes where radioactive decay in experimental 
window in non-negligible (as is the case for the synthesis of many PET radiotracers), decay-
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corrected RCYs are insufficient to describe the evolution of the activity associated with different 
radiochemical species over time.  
The absolute and relative activity of a radioactive product at any time point is given by the 
non-decay-corrected activity yield. Activity yield is defined as, ‘…the overall activity of a 
radioactive product isolated from the production of a radiolabelled compound or 
radiopharmaceutical.’(23) Activity yields are normally expressed in units of activity (Bq) but 
values can also be normalised to the initial activity and reported as a percentage (%). This step 
facilitates comparison with chemical yields (%) and is convenient for kinetic analysis.  
It is important to note that the chemical yield and the activity yield differ when radioactive 
decay is non-negligible during the process. Although high chemical yields are desirable, the 
maximum activity yield does not necessarily coincide with peak chemical conversion. For 
instance, once the reaction given by Equation 1 is complete, the chemical yield (and RCY) are 
100% at all time points, but the activity yield is time-dependent and decreases by the factor, )*+,-. . Here, A0 is the initial activity in Bq, l / s-1 is the decay constant, and t is the time difference 
between the initial and final activity measurements. A chemically efficient, quantitative reaction 
is of no use in radiochemical synthesis if it proceeds too slowly and the activity has decayed before 
the product can be isolated/used. Therefore, optimisation of radiolabelling reactions requires 
identifying conditions that give the highest activity yield. Methods for calculating activity yields 
based on standard reaction kinetic schemes are presented in the following sections.  
 
First-order and pseudo-first-order radiochemical reactions 
The majority of radiolabelling reactions involve a bimolecular process (Equation 1). Exceptions 
include Szilard-Chalmers-type processes where a radioactive product is isolated after unimolecular 
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degradation of an irradiated target material or radioactive parent species. Szilard-Chalmers 
reactions are not relevant for PET radiochemistry and are not considered further. In addition, the 
kinetic analysis of first-order reactions follows the same derivation as pseudo-first-order reactions, 
the latter of which is given below.  
Biomolecular reactions can be described by a second-order rate law (Equation 2) where the 
observed initial rate is dependent on the initial concentrations, [A]0 and [B]0. −0[2]0. = − 0[5]0. = 0[6]0. = 78[A][B]  (Equation 2) 
In situations where [B]0 >> [A]0 (normally accepted to be a ~100-fold molar excess of species B 
in standard kinetic studies), the method of isolation can be used to simplify the analysis via the 
pseudo-first-order approximation (Equation 3; where the observed rate constant, kobs = k2[B]0). −0[2]0. = 79:;[A]  (Equation 3) 
Most radiolabelling reactions can be designed to obey pseudo-first-order kinetics through 
judicious choice of the starting conditions. However, in later sections it will be shown that data on 
the clinical production of four different radiopharmaceuticals indicate that caution should be used 
before making assumptions about the mole ratio of reactants (vide infra). Integrated rate laws for 
a pseudo-first-order reaction that give the chemical concentrations [A] and [P] versus time are 
given by Equations 4 and 5, respectively.  [A] = [A]*+,%<=>.  (Equation 4) [P] = [A]*(1 − +,%<=>.) (Equation 5) 
If species A and P are radioactive, the calculation of activity yield requires that concentrations be 
modified to account for radioactive decay during the reaction. Decay-corrected formulae are given 
by Equations 6 and 7, where AX is the activity yield of species X at time t. Values of AX can be 
expressed as a percentage by normalising to the initial activity, A0 at t = 0 s.  
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)2 = [A]+,-. = [A]*+,(%<=>B-).   (Equation 6) )6 = [P]+,-. = [A]*(1 − +,%<=>.) ⋅ +,-.   (Equation 7) 
A kinetic plot showing the change in chemical yields of species A, B and P, and the activity yield 
AP versus time is shown in Figure 2A. Starting conditions were defined from the clinical 
radiosynthesis of [18F]FDG (see Table 1 [vide infra], and Supporting Information Table S1). In 
this example, the theoretical maximum activity yield, AP(max.), is ~82% and occurs at ~24 min., 
but the maximum chemical conversion (here, where both the chemical yield [P], and RCY, equal 
100%) does not occur until ~45 min. Interestingly, when AP reaches a peak, the total activity in the 
sample is ~86% which means that the radiochemical purity (RCP) is only ~96%. If the reaction is 
allowed to proceed until complete chemical conversion, the radiochemical purity (RCP) 
approaches 100% asymptotically, but at the expense of decreasing the theoretical AP(max.) to 
~75% at 45 min. These data illustrate the compromise that must be made between activity yields 
and RCP when optimising radiolabelling reactions. 
When new reactions are developed, their potential use in radiochemistry is governed by 
many factors. These factors include (among others): the chemically efficiency (yield) of the 
process; accessibility, stability, solubility and reactivity of the radiolabelling precursors; regio- and 
stereo-selectivity of the products; and functional group tolerance / substrate scope etc. Reaction 
rates are also crucial in deciding if a new reaction will work in a radiochemical setting. Figure 2B 
shows the variation in AP versus time, as the overall reaction rate changes by variation in kobs from 
0.02 s-1 to 0.0002 s-1. The rates of inherently slow reactions can be increased by using more 
precursor, but solubility and competing side reactions often place limits on the maximum value of 
[B]0. Clinical syntheses of [18F]FDG use a relatively large amount of precursor (ca. 10 – 30 mg), 
but such high values are not common in radiochemistry where a secondary goal of optimisation is 
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to reduce [B]0. Therefore, the data in Figure 2B suggest that for successful application in 18F-
radiochemistry, new reactions should aim have observed rate constants for nucleophilic SN2 
substitution by fluoride anions at least ~0.001 M-1 s-1 (pink line). This lower boundary to the value 
of kobs ensures that the reaction reaches maximum AP within a reasonable reaction time of <60 min. 
To maintain this limit on kobs when using lower amounts of radiolabelling precursor, the inherent 
reaction rate (given by the value of k2) in general must be >0.1 M-1 s-1. 
 Similar analyses can be performed for different radionuclides. Pseudo-first-order kinetics 
calculated using the same starting conditions as employed in Figure 2A, but switching the 
radionuclide to 15O, 13N, 11C, 68Ga, 64Cu, and 89Zr, are shown in Figures 3A – 3F, respectively. 
Values of the corresponding AP(max.) and RCP are given in Supporting Information Table S1. For 
long-lived radionuclides like 89Zr, and to a lesser extent 64Cu, activity yields mirror closely the 
chemical yield or RCY in the region before AP reaches a maximum. For example, when AP reaches 
a theoretical peak, corrections for activity yield constitute a difference of <1% for 89Zr, and <4% 
for 64Cu, versus the chemical yield or decay-corrected RCY. Therefore, for most radiolabelling 
processes that use radionuclides where the physical half-life is >10 times the reaction window, 
effective reaction optimisation can be accomplished on the basis of standard chemical yields or 
RCYs, without introducing significant loss of activity in the final product.  
For short-lived radionuclides like 15O, 13N, 11C, 18F and 68Ga, a pronounced difference 
occurs between AP(max.) and the chemical yield or RCY. Analysis indicates that under otherwise 
equivalent conditions, for 11C-radiolabelling reaction to achieve a theoretical AP(max.) of ~90%, 
the observed reaction rate must increase by a factor of 10 compared with processes that involves 
18F. Hence, for applications in radiopharmaceutical synthesis, new 11C-radiolabelling reactions 
should aim to have higher inherent reactions rates with an approximate value of k2 >1.0 M-1 s-1. A 
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10-fold increase in rate is readily attainable in 11C- and 13N-radiochemistry, but the situation for 
15O is more challenging. The very short half-life of 15O requires that (ideally) the reaction goes to 
completion in ~10 to ~15 s. This means that only very fast and efficient reactions, with k2 > ~102 
M-1 s-1 can be considered for radiosynthesis with 15O. To place these rate constants in context, 
strain-promoted, copper-free ‘click’ reactions are some of the fastest bioorthogonal reactions 
known, and are commonly used for imaging applications in vitro and in vivo using pretargeted 
strategies.(24–31) Reported second-order rate constants between azides or tetrazine derivatives, 
and various strain-promoted alkene or alkyne reagents range from ca. 0.1 to >103 M-1 s-1 (Figure 
4).  
 
Second-order radiochemical reactions 
It is important to note that for standard biomolecular reactions, the use of a second-order kinetic 
scheme is almost always correct, even when the reactions are performed under pseudo-first order 
conditions. Data from the clinical production of [68Ga]GaPSMA-11 and [89Zr]Zr-DFO-J591 
indicate that (as performed experimentally) these reactions conform to second-order kinetics 
(Equation 1 and Table 1 [vide infra]). When [A]0 ¹ [B]0, the integrated second-order rate law is 
given by Equation 8. ln F[5][2]G = lnF[5]H[2]HG − 78I  (Equation 8) 
Chemical concentrations, [A] and [P], can be derived in the standard fashion,(1,2) and activity 
yields of species A and P versus time are given by Equations 9, and 10, respectively, (where the 
constant, D0 = [B]0 – [A]0).  )2 = [A]+,-. = ∆H[2]H[5]HK∆HL&M,[2]H ⋅ +,-. (Equation 9) 
 Page 12 
 
)6 = [P]+,-. = [2]H[5]HNO,K∆HL&MP[2]H,[5]HK∆HL&M ⋅ +,-. (Equation 10) 
From the reaction stoichiometry, and by the law of mass balance, the chemical concentration [B] 
versus time is given by Equation 11.  [B] = ∆* + [A] (Equation 11) 
Second-order kinetic plots showing the change in the chemical yields of species A, B and P, and 
the activity yield AP versus time are presented in Figures 5A and 5B. Starting conditions were 
defined from the clinical radiosynthesis of [68Ga]GaPSMA-11 and [89Zr]Zr-DFO-J591 (see Table 
1 [vide infra] and Supporting Information Table S2). 
Most radiolabelling reactions with 68Ga and 89Zr should be modelled as a second-order 
process. In fact, it is likely that many of optimised radiolabelling reactions that use metal-based 
radionuclides follow second-order kinetics. The reason for this is simple – radiometal chemists 
usually perform test reactions to evaluate the molar activity of the radionuclide source, and the 
final product. On scaling up the reactions for production, starting conditions are usually chosen to 
ensure that the final RCYs and RCPs are close to 100%. This approach has the potential advantage 
of eliminating the need to perform lengthy purification steps to increase RCP before the product 
can be used. Although, even in processes that avoid purification, the presence of other chemical 
impurities must be tested before a product can be released. 
In both preclinical and clinical work, 68Ga-radiolabelling reactions are usually complete 
within 5 – 10 min, whereas 89Zr-radiolabelling of antibodies requires 45 – 60 min. Kinetic 
calculations indicate that the radiosynthesis of [68Ga]GaPSMA-11 has a second-order rate constant 
of approximately k2 ~103 M-1 s-1. Radiolabelling to produce [89Zr]Zr-DFO-J591 occurs at a slightly 
slower rate with k2 in the range ~102 – 103 M-1 s-1. Clinical starting conditions are similar for these 
two reactions with the total moles of A and B in the range 10 – 30 nmol, and initial activities of 
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~500 – 1000 MBq. When other factors such as differences in reaction temperature and volume are 
considered, it appears that radiometallation of the HBED-CC by 68Ga3+ ions, and desferrioxamine 
B (DFO) by 89Zr4+ ions, occur at comparable rates.  
The striking feature is that radiometallation with 68Ga3+ and 89Zr4+ ions using these acyclic 
chelates occurs spontaneously at reaction rates that are ~102 to ~104 times faster than most 
reactions used in 11C- and 18F-radiochemistry. This is exemplified by the fact that radiometal ion 
chelation occurs under mild conditions (room temperature) whilst many 11C- and 18F-reactions 
usually require elevated temperatures to drive product formation. In addition, fewer side-products 
(both chemical and radiochemical) are observed in metal-based radiochemistry than in normal 11C- 
and 18F-radiolabelling processes. High reaction rates and efficient chemical conversion mean that 
for metal-based radiochemistry, initial amounts of precursor B can be reduced to ~10-8 mol (where 
[B]0 ~10-5 M; Table 1 [vide infra]). These initial starting concentrations are around 102 – 103 times 
lower than typical starting concentrations of 11C- and 18F-radiolabelling precursors – consistent 
with the difference in estimated rate constants.  
The reader should note that metal ion complexation reactions are not always rapid. 
Thermodynamic barriers mean that efficient radiometallation of cyclic chelates like DOTA, and 
the cross-bridged variant CB-TE2A, with 64Cu2+ requires heating to around 60 – 95 oC.(32) 
Nevertheless, the high thermodynamic driving forces for complexation, and the relative kinetic 
ease of displacing mono- or didentate ligands with multidentate chelates, mean that radiometal 
ions are often the first choice for accessing radiotracers (like many radiolabelled peptides) that 
cannot be radiolabelled efficiently with existing 11C- or 18F-chemistry. 
 
Parallel or competing radiochemical reactions  
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The methods used to derive activity yields in pseudo-first-order and second-order radiolabelling 
reactions can be readily adapted to any kinetic scheme. As illustrated, some radiolabelling 
reactions, including 68Ga-radiolabelling of peptides and 89Zr-radiolabelling of antibodies can be 
considered as ‘ideal’ in that they go to completion rapidly with essentially no side-product 
formation. This is not the case for the synthesis of most 11C- and 18F-radiopharmaceuticals where 
complex mixtures of both radioactive and non-radioactive products are frequently encountered. 
Modelling the kinetics of complex reactions like the radiosynthesis of [18F]FDG or [11C]raclopride 
(Figure 1) is non-trivial.  
In general, the use of more complex kinetic schemes that involve parallel or competing 
reactions are required to account for the formation of multiple chemical and radiochemical 
products. For example, in the clinical radiosynthesis of [18F]FDG, the desired product is the main 
radioactive component (ca. 50% – 60% RCY in ~50 min.)(18) but a number of poorly 
characterised radiochemical species are also formed. Typical starting conditions in [18F]FDG 
radiosynthesis obey the pseudo-first-order approximation, where [B]0 = ~100[A]0 (Table 1). At 
the end of synthesis, the chemical component of [18F/19F]FDG in the final reaction mixture 
constitutes only about ~0.5% to ~1.0%. Stoichiometric studies have also shown that the major 
chemical species can be assigned to elimination and hydrolysis products, yet a significant fraction 
(ca. ~25%) of the mass balance is composed of unknown compounds (Figure 6).(33)  
Under pseudo-first-order conditions where [B]0>>[A]0, productive radiochemical 
reactions that give different radioactive species can be decoupled from the main chemical 
degradation pathway of species B. Note: Decoupling is valid as long as the pseudo-first-order 
approximation holds, but in cases where significant change in [B] occurs, it is safer to treat the 
radiochemical reaction as a second-order process. A generalised parallel reaction scheme is given 
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by Equations 12 and 13, where the species Pi are radioactive products formed under pseudo-first-
order conditions, and species Dj are non-radioactive ‘degradation’ products. Equation 13 serves as 
a simplified example that models the chemical degradation of B as multiple, competing, first-order 
processes. Degradation pathways such as hydrolysis and elimination usually involve more 
complex rate laws with pronounced solvent effects and acid/base dependency. With more accurate 
more experimental data, Equation 13 can be easily modified to account for more complex reactions 
or an increasing number of competing reactions.  A	 + 	B	 %Q→ 	PR 					S = 1, 2,… W  (Equation 12) B	 %X→	DZ					[ = 1, 2,… W  (Equation 13) 
During the time period that pseudo-first-order conditions remain valid, the analytical solution for 
the activity yield of species A is given by Equation 6 (vide supra; note that the second-order 
integrated law given by Equation 9 can also be used), and that of species Pi is given by Equation 
14, where 7\ = ∑ 7RR^_O .  )6Q = [PR]+,-. = %Q[2]H%` N1 − +,%`[5]H.P ⋅ +,-.  (Equation 14) 
From stoichiometric studies reported by Brown et al., the relative product yields can be used to 
estimate the ratio of the rate constants between the SN2 reaction with fluoride and competing 
reactions of B that lead to elimination, hydrolysis, and other unknown products (Equation 15).  
[6a][6&] = %a%& (Equation 15) 
The chemical yields of the main species identified from stoichiometric reactions performed under 
the same conditions as the radiosynthesis are <5% of [19F]FDG from the desired SN2 substitution, 
29% of a,b-glucose from hydrolysis, and 42% (2R,3R)-3-hydroxy-2-(hydroxymethyl)-2,3-
dihydro-4H-pyran-4-one from elimination. The remaining ~24% of the mass balance was 
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associated with unidentified side-products. From these data, it can be deduced that the SN2-
substitution rate is ~8.4 times slower than the main chemical degradation pathway (elimination) 
and ~5.8 times slower than hydrolysis pathway that yields glucose. Using these data, combined 
with the reaction scheme given by Equations 12 and 13, and starting conditions derived from data 
on the clinical production (Table 1), it is possible to simulate the chemical and radiochemical 
kinetics of [18F]FDG synthesis. Kinetic plots showing the calculated percentage change in the 
chemical and activity yields of different species present in the radiopharmaceutical synthesis of 
[18F]FDG are shown in Figures 7A and 7B, respectively. The model includes four different 
reaction pathways of species B yielding ‘products’ D1 – D4. In Figure 7A, the chemical yield [D1] 
is equivalent to the total chemical yield of all radioactive products, [Pi], formed from the reaction 
of A with B. The chemical yields, [D2] and [D3] are assigned to the elimination and hydrolysis 
products, respectively, and [D4] accounts for the presence of unknown species. From the plot of 
chemical yields it can be seen that the components of the reaction mixture that are formed by the 
reaction of A and B constitute only a small fraction of the total chemical content (blue line). The 
fraction is given by the ratio [A]0/[B]0, and here is <1%. The time-evolution of the activity yields 
of radioactive species P1 – P4 is shown in Figure 7B. Species P1 is assigned to the desired product 
[18F]FDG and here is formed in ~67% RCY at completion. Arbitrary species P2 – P4 are simulated 
to show how the model can be adapted to incorporate the formation of several unknown radioactive 
byproducts. Here, clinical production data were used to set the starting conditions, and the 
maximum activity yield AP1 ([18F]FDG) is ~57% at 18 min. This value is consistent with the 
observed activity yields in [18F]FDG productions.(18) Accurate kinetic models depend on the 
conditions used in an individual radiosynthesis. This example illustrates how a detailed knowledge 
of chemical kinetics can be used to understand the time evolution of different species in even the 
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most complex radiolabelling mixtures. Importantly, the methods developed here can be readily 
adapted to increasingly complex reactions, including those that involve catalysis, phase transfer 
reagents or generation of reactive species via electrochemical or photoactivation processes. 
 
 
Initial conditions in radiolabelling reactions: defining [A]0 
The molar activity problem 
Previous sections introduced the theory of radiochemical kinetics but the accuracy of a kinetic 
model in describing a reacting system relies on knowledge of the starting conditions. In standard, 
non-radioactive chemical kinetics, the initial concentrations can be controlled easily, but in 
radiochemistry the situation is more complex. Table 1 contains experimental data on the properties 
of the radionuclide source (species A), and on the radiochemical syntheses of four prominent PET 
radiopharmaceuticals: [11C]raclopride,(15–17) 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG),(18) 
[68Ga]GaPSMA-11,(19) and the antibody-based agent [89Zr]Zr-DFO-J591 (Figure 1).(20–22) For 
comparison, preclinical data are also given for [89Zr]Zr-DFO-J591.(20)  
The starting concentration of precursor [B]0 is usually well-known. The initial activity of 
species A is also measured routinely. Conversion of the activity of species A into the number of 
moles (or concentration) requires accurate determination of the molar activity, As / MBq nmol-1. 
For preclinical work with many radioactive metal ions, the apparent molar activity can be 
measured by using isotopic dilution assays.(34) In contrast, in most clinical processes that use 11C 
or 18F, the molar activity of the radionuclide source is not normally measured. Representative 
molar activities for 11C and 18F (Table 1) were extrapolated from the seminal review by Lapi and 
Welsh.(35) Experimental values for 11C, 18F, 68Ga and 89Zr are between 0.1% to 3.0% of the 
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theoretical maximum molar activity, As(max.) (calculated by Equation 16; where NA is Avogadro’s 
constant).  )b(max. ) = 	g2 ∙ i  (Equation 16) 
It is important to note that As(max.) depends on the half-life. Therefore, care must be taken 
when comparing the molar activities of different radionuclides. For instance, a molar activity of 
43.1 MBq nmol-1 of 89Zr is chemically equivalent to the much higher value of 1850 MBq nmol-1 
of 18F. Isotopic dilution factors (IDFs) account for this difference and allow direct comparisons 
between different radionuclides (Equation 17).  IDF = 	 l>(mno.)l>   (Equation 17) 
Except in special stoichiometric circumstances, IDF-values are always ³1, where higher ratios 
indicate that the radionuclide sample is diluted with an increasing amount of non-radioactive 
isotopes. Comparison of the radionuclide IDFs listed in Table 1 indicate that 18F and 89Zr 
radionuclide sources contain a similar number of non-radioactive isotopes. In the case of 89Zr and 
other radiometal ions, the apparent (or effective) molar activity measured by chemical methods 
includes the contribution from other chemically similar metal ions that compete for the chelate. 
For instance, Fe3+ ions successfully compete with 89Zr-radiolabelling reactions for complexation 
by DFO and other siderophores. As an alternative, induction-coupled plasma mass spectrometry 
(ICP-MS) can be used to measure the true molar activity for most radiometal ions but this tool is 
not often available in radiochemical facilities. IDF values for 11C-sources are comparatively high 
due to the difficulties in removing sources of carbon contaminations from the process.(35) IDF 
values of 68Ga eluted from a standard 68Ge/68Ga generator (Eckert&Ziegler) are estimated be 
between ca. 500 – 1000, which indicates that there is still considerable scope to improve the molar 
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activity of most 68Ga-radiotracers. However, the values for 68Ga are comparable to many clinical-
grade 11C-radiolabelling reactions.  
Reported values of radionuclide molar activity of 11C and 18F show substantial variation 
for many reasons. For example, the methods and materials used in the cyclotron production are 
known to have a strong influence on the molar activity.(35) Füchtner et al.(36) demonstrated that 
systematic cleaning procedures can reduce chemical contaminants in 18F samples.(36) However, 
the other reagents and solvents used in a reaction also introduce contaminants, and additional time 
constraints make it technically challenging to determine the apparent molar activity at the start of 
each synthesis. Therefore, the molar activity of a radionuclide source is not a reliable way of 
defining [A]0 in radiochemical kinetics, and an alternative estimate must be found.  
  
Molar activity of the radiochemical product 
In 1:1 stoichiometric reactions (Equation 1), the initial molar activity of the radionuclide gives the 
theoretical upper limit to the (decay-corrected) molar activity of the final product. However, this 
upper limit is poorly defined, and the omission of additional contaminants introduced in the 
reaction mixture mean that this value cannot be used to define [A]0. In contrast, the molar activity 
of an isolated radiopharmaceutical (P) is measured routinely and includes the contribution from 
all sources of contaminants present in each individual reaction. Consequently, the product molar 
activity gives an accurate estimate of the lower limit of initial molar activity of species A at t = 0 
s, and is therefore, a suitable alternative for defining [A]0.  
One caveat is that reported molar activities of the product are not always decay-corrected 
to the start of the experiment. Decay corrections can be performed if the reaction time is 
documented, but since most PET radiotracer syntheses are completed within one half-life, the use 
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of non-decay corrected values will only overestimate [A]0 by a factor of ~2. To place this error in 
context, [B]0 is often systematically varied over ~2 orders of magnitude during radiochemical 
optimisations. For example, the initial mass of precursor B used in many 11C- and 18F-
radiolabelling reactions is in the range 0.1 to 10 mg. Systematic variations and non-reproducible 
experimental uncertainties in precursor mass are likely to have a larger impact on reaction rates 
than the aforementioned error that is introduced by estimating [A]0 from molar activity of the 
isolated products. In the absence of more accurate measurements of molar activities inside 
individual reactions at t = 0 s, the use of the product molar activity is recommended for estimating 
[A]0 in radiochemical kinetics. 
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Table 1. Representative properties of four clinical-grade PET radiopharmaceuticals radiolabelled with 11C, 18F, 68Ga, or 89Zr. 
 Radiopharmaceutical or radiolabelled compound 
Parameter 
[11C]raclopride 
(clinical) a 
[18F]FDG 
(clinical) b 
[68Ga]GaPSMA-11 
(clinical) c 
[89Zr]Zr-DFO-
J591 (clinical) d 
[89Zr]Zr-DFO-
J591 (preclinical) e 
 
Properties of the radionuclide source 
Half-life, t1/2 20.364 min. 109.7 min. 67.71 min. 78.41 h 78.41 h 
Half-life, t1/2 (s) 1221.8 6582.0 4062.6 282276.0 282276.0 
Decay constant, l (s-1) 5.6730 ´ 10-4 1.0531 ´ 10-4 1.7062 ´ 10-4 2.4556 ´ 10-6 2.4556 ´ 10-6 
Radionuclide reagent [11C]CH3I or 
[11C]CH3OTf [
18F][K(K222)]F [68Ga][Ga(H2O)6]Cl3 [89Zr][Zr(C2O4)4]4– [
89Zr][Zr(C2O4)4]4– 
Radionuclide molar activity (MBq 
nmol-1) 555 – 1850 
f 1850 g  100 – 200 h  17 – 45 i 17 – 45 i 
Theoretical maximum molar 
activity, As (max.) (MBq nmol-1)h 341626.75 63417.39 102745.34 1478.74 
1478.74 
Isotopic dilution factor (IDF) 615.5 – 184.7 34.3 1027.5 – 513.7 87.0 – 32.9 87.0 – 32.9 
 
Properties of the radiopharmaceutical synthesis  
Initial activity (MBq) 37000 (1 Ci) 37000 (1 Ci) 1000 555 153.2 
Precursor mass (mg) 1.0 10 0.01 3 0.84 
Precursor molecular weight (g mol-
1) 
333.21 480.37 947.0 ~150,000 ~150,000 
Nanomoles of precursor B at t = 0 
s (nmol) 
3.00 ´ 103 2.08 ´ 104 10.6 20 (antibody) 5.6 (antibody) 
No. of chelates per mAb Not applicable Not applicable Not applicable 1.0 – 1.5 3.9 
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Nanomoles of chemically 
accessible chelate (nmol) 
Not applicable Not applicable Not applicable 20.0 – 30.0 21.84 
Typical reaction time (min) 
0.5 – 5 (HPLC loop) 
5 – 20 (vial) 
5 – 45 5 – 10 45 – 60 45 – 60  
Total production time (min) 30 – 45 30 – 90 30 – 45 60 – 120 60 – 120 
Molar activity of the isolated 
product (MBq nmol-1) 
770 185 100 23.3 7.01 
IDF 443.7 342.8 1027.5 63.5 210.9 
Percentage of As (max) 0.23% 0.29% 0.10% 1.58% 0.47% 
Nanomoles of radioactive species 
A at t = 0 s (nmol) 
48.1 200 10.0 23.8 21.85 
Mole ratio (B0 / A0) at t = 0 s 62.5 104.1 1.06 0.84 – 1.26 j 1.00 j 
Theoretical maximum RCY (decay 
corrected) 
100% 100% 100% 84% – 100% j 100% j 
Reported isolated RCY (decay 
corrected) 
3.0% 50% – 60% >98% 70% – 100% 77% 
 
a Data on [11C]raclopride were provided by Prof. Neil Vasdev and Dr Armando Garcia, Centre for Addiction and Mental Health, 
University of Toronto, Canada, and also adapted from the recent work of Shao et al.(15) 
b Data on the nucleophilic synthesis of [18F]FDG using the mannose triflate precursor(18) were provided Dr Lee Collier, Advion Inc., 
Ithaca, New York, USA. 
c Data on the clinical production of [68Ga]Ga-PSMA-11 were provided by Dr Mark Bartholomä, University Hospital Freiburg, Germany, 
and selected data used from reference (37). 
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d Data on the clinical production of [89Zr]Zr-DFO-J519 were provided by Dr Serge Lyashchenko and Prof. Jason S. Lewis, Memorial 
Sloan-Kettering Cancer Center, New York, USA. Equivalent data were also observed for the clinical production of [89Zr]Zr-DFO-
trastuzumab.(38) 
e Data on the preclinical production of [89Zr]Zr-DFO-J519 are from reference (20). 
f The range is based on an assessment of typical molar activities reported by Lapi and Welch(35), and in the work of Larsen et al.(39) 
g Füchtner et al.(36) reported a value of 43.0 GBq nmol-1 (IDF ~1.5; equivalent to ~68% of the theoretical maximum, As) for the molar 
activity of [18F]fluoride anions produced by the 18O(p,n)18F nuclear transmutation reaction using [18O]H2O.(35,40) A more realistic 
value is 1850 – 3700 MBq nmol-1 for the [18F]fluoride anion source (IDF between 34.3 – 17.1; equivalent to between 2.9% and 5.8% of 
the theoretical maximum molar activity, As). 
h Holland and Bartholomä, unpublished data. 
i Holland et al.(34)  
j Note that the mole ratio and theoretical maximum yields for work with antibodies are calculated based on the number of moles of 
accessible chelates. This value is equal to the number of moles of antibody, n(mAb), multiplied by the experimentally measured number 
of accessible chelates per mAb. 
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Radiolabelling reaction rates 
How fast are current radiopharmaceutical reactions? By using radiochemical kinetic models 
coupled with the starting conditions given in Table 1, it is possible to estimate how fast a reaction 
must be for it to be potentially useful in radiopharmaceutical synthesis. The estimated ranges of 
observed second-order rate constants (k2-values) derived from radiolabelling reactions using 11C, 
18F, 68Ga and 89Zr are shown in Figure 8. The estimated k2-values of 18F-fluorination reactions 
show a wide range of reaction rates. This is consistent with the diverse chemistry used in typical 
SN2-substitution reactions which are strongly dependent on the reaction conditions, the solvent 
composition, ionic strength, and the chemical nature of the substrate and the leaving group. 
Furthermore, 18F-fluoriantion reactions are often performed using catalysts or phase transfer 
reagents that can strongly influence reaction mechanisms and rate constants. For these reasons, 
modelling the kinetics of a broad range 18F-radiolabelling reactions is likely to present additional 
challenges beyond those faced in most other areas of radiochemistry. In contrast, that majority of 
11C-radiolabelling reactions involve methylation of amines, alcohols and thiols using reagents 
including [11C]CH3I and [11C]CH3OTf. Again, the kinetics depend on the conditions, but in 
general, the nucleophilic substitution reactions employed in the clinical production of many 11C-
radiopharmaceuticals proceed at similar rates. This observation is reflected in the narrower 
distribution of estimated k2-values for 11C-reactions compared to 18F-radiochemistry. 
Radiometallation reactions depend on the nature of the chelate/complex but are usually fast with 
estimated rate constants that can exceed k2 >103 M-1 s-1. These values mean that radiolabelling 
with metal radionuclides can often be performed in stoichiometric ratios leading to second-order 
kinetics.  
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When developing new reactions for potential use in radiochemistry, reaction rate is one of 
the critical factors that will determine if the process can deliver sufficient activity yield. If 
measured reaction rates fall within the range of existing radiolabelling technologies, it is likely 
that the new process can be adapted for use in radiopharmaceutical synthesis. Fast reaction rates 
are usually desirable because they facilitate higher radiochemical conversion and higher isolated 
activity yields. However, slower or more complex reactions in which the desired radiochemical 
species is not the main radioactive component of the mixture can also be used when low activity 
yields are acceptable. For instance, when a single imaging dose is required (ca. ~185 to ~740 
MBq), activity yields of <1% may still provide enough product, so long as the reaction can be 
scaled for use with high initial activities.  
 
Conclusions 
Chemical kinetic theory has been extended to describe reactions in which different reactants and 
products undergo radioactive decay during the observation window. Corrections for radioactive 
decay are straight-forward, and the methodology can be applied to kinetic schemes of any order or 
complexity. Evaluation of clinical data on current radiopharmaceutical products reveals that, 
contrary to common perceptions, not all radiolabelling reactions obey pseudo-first-order kinetics. 
Second-order kinetic schemes are appropriate for many radiolabelling reactions that involve 
complexation of 68Ga3+, 89Zr4+ and other radiometal ions. Fluorination reactions using 
[18F]fluoride, and some 11C-radiolabelling reactions are likely to follow pseudo-first-order kinetics 
but the variability in the molar activity of the radionuclide source, and potential contaminants 
introduced in the reaction, may switch the kinetics toward second-order. Radiochemical kinetics 
can be used to model complex reactions, like [18F]FDG radiosynthesis, that involve parallel or 
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competing processes at both the chemical scale of the precursor, and the radiochemical scale of 
the radionuclide. Finally, it is hoped that more students of radiochemistry will find radiochemical 
kinetics useful when developing new radiolabelling reactions and improving current 
radiopharmaceutical syntheses.  
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Figure legends 
Figure 1. Chemical structures of the radiopharmaceuticals [11C]raclopride, [18F]FDG, 
[68Ga]GaPSMA-11, and the antibody-based agent [89Zr]Zr-DFO-J591. 
 
Figure 2. (A) Plot showing the change in chemical yields of species A, B and P, and the activity 
yield of P versus time under pseudo-first-order kinetics. Starting conditions were defined by data 
on the clinical production of [18F]FDG. Note the difference between radioactive decay at time t 
(black line) and the activity yield AP(t) is a measure of the radiochemical purity of species P. (B) 
Plot showing the change in activity yield, AP, as the reaction rate decreases from kobs = 0.02 to 
0.0002 s-1 (where [B]0 = 20.8 mM). 
 
Figure 3. Pseudo-first-order kinetic plots illustrating the effect of using radionuclides with 
different half-lives on the chemical and activity yields of species A, B and P versus time. Starting 
conditions are identical to those used in Figure 2A. (A) 15O (t1/2 = 122.24 s). (B) 13N (t1/2 = 9.965 
min.). (C) 11C (t1/2 = 20.364 min.). (D) 68Ga (t1/2 = 67.71 min.). (E) 89Zr (t1/2 = 78.41 d). NB: for 
the 89Zr plot, the curves for [P] (blue) and AP (pink), as well as the curves for radioactive decay 
(black) and [B]0 (green) overlap in this experimental window. 
 
Figure 4. Structures of several prominent bioorthogonal reagents used in fast, strain-promoted 
copper-free ‘click’ conjugation reactions in vitro and in vivo.(25,31) Reactions between azides and 
strained cyclooctynes have rate constants (k2) between 0.1 – 1.0 M-1 s-1, whereas trans-
cyclooctenes react with tetrazine derivatives under aqueous condition with rate constants >103 M-
1 s-1.(24,28)  
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Figure 5. Second-order kinetic plots showing the change in chemical yields of species A, B and 
P, and activity yield AP versus time. Plots were calculated using data derived from the clinical 
production of: (A) [68Ga]GaPSMA-11, and (B) [89Zr]Zr-DFO-J591. Second-order rate constants 
are shown inset (Table S2).  
 
Figure 6. Reaction scheme showing some of the products formed in the synthesis of [18/19F]FDG. 
Chemical yields are adapted from the work of Brown et al.(33) 
 
Figure 7. Kinetic plots calculated using preclinical and clinical data on the radiochemical synthesis 
of [18F]FDG. (A) Percentage change in the chemical yield of species A, B and Dj versus time. Note 
that [D1] is equivalent to the total chemical concentration, [P](total), of all species formed by the 
reaction of A with B, the main component of which is assigned to SN2 substitution leading to 
[18F]FDG. Species D2, D3 and D4 are assigned to reactions that yield the elimination, hydrolysis 
and unidentified products, respectively, from the chemical degradation of precursor B. (B) 
Percentage change in the activity yields of species A and Pi versus time. Species P1 is equivalent 
to the desired [18F]FDG product which in this simulation is obtained in ~67% chemical yield. 
Species P2, P3 and P4 are assigned to unidentified radioactive byproducts, and are shown to 
illustrate how the kinetic scheme can be adjusted to account for parallel/competing radioactive 
side-reactions.  
 
Figure 8. Chart showing the estimated range of second-order rate constants, k2 / M-1 s-1 in 
successful clinical radiopharmaceutical syntheses using 11C, 18F, 68Ga or 89Zr.  
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